SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
Neo-Kan, NCT05472623: Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab |
|
|
| Active, not recruiting | 2 | 42 | US | Adagrasib, Adagrasib/Nivolumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Mirati Therapeutics Inc., Bristol-Myers Squibb | Resectable Non-Small Cell Lung Cancer | 11/25 | 02/29 | | |
NCT05254184: KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC |
|
|
| Recruiting | 1 | 12 | US | Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides, Nivolumab 3 mg/kg every 2 weeks, Ipilimumab 1 mg/kg every 6 weeks | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Non-Small Cell Lung Cancer | 04/25 | 04/27 | | |
NCT05375084: SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation |
|
|
| Terminated | 1 | 21 | US | BBP-398 with nivolumab | Navire Pharma Inc., a BridgeBio company, Bristol-Myers Squibb | Non Small Cell Lung Cancer, Solid Tumor | 04/24 | 07/24 | | |
